|
|
 |
| MACS® GMP PepTivator® HCMV pp65 |
|
| Description |
Human cytomegalovirus (HCMV) is a member of the herpes virus group and belongs to the subfamily of beta-herpes viruses. Between 50 and 85% of human adults are infected with HCMV. Once infected, the virus persists in the organism. The infection is asymptomatic in healthy individuals but in immunocompromized patients HCMV can cause severe disease.
The pp65 protein (65 kDa lower matrix phosphoprotein), also known as glycoprotein 64 or UL83, is a virion tegument protein and the main component of the enveloped subviral particle. pp65 is an immunodominant target of CD4+ as well as CD8+ T cell responses to HCMV.
The MACS GMP PepTivator™ HCMV pp65 is a peptide pool that consists mainly of 15-mer peptides with eleven amino-acid overlap. It has been developed for efficient in vitro stimulation and subsequent isolation of HCMV pp65-specific CD4+ and CD8+ T cells.
One vial contains 60 nmol/peptide for the stimulation of 109 total cells. |
| Applications |
Antigen-specific T cells play a critical role in the regulation of immune responses and the elimination of virus-infected or malignant cells in the human body. Adoptive transfer of clinical-grade pp65-specific CD4+ and CD8+ T cells is a valuable tool for the treatment of HCMV infections after hematopoietic stem cell transplantation (SCT)1,2 and shows potential for solid organ transplantation (SOT)3.
The in vitro stimulation of pp65-specific CD4+ and CD8+ T cells with MACS® GMP PepTivator HCMV pp65 causes the production of the effector cytokine IFN-gamma. The secretion of IFN-gamma then permits the enrichment of pp65-specific effector/memory T cells with the use of the CliniMACS Cytokine Capture System (IFN-gamma). |
| | |
|
 |
| My favorites |
| Your current favorite list is empty. |
|
| Products |
| MACS GMP PepTivator HCMV pp65 |
| For research or ex vivo cell culture processing |
| Availability: Worldwide (1) |
Download datasheet 170-076-109
|
| (1) For availability in your country please contact your local representative. |
|
| References |
| 1. Einsele et al. (2002) Blood 99: 3916–3922. |
| 2. Mackinnon et al. (2008) Blood Cells Mol. Dis. 40: 63–67. |
| 3. Brestrich et al. (2009) Am J Transplant. Jul;9(7):1679-84. |
| 4. |
|
|
|
© 1999 - 2010 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|